Systemic sclerosis after interferon alphacon-1 therapy for hepatitis C

Internal Medicine

Volumn 46, Issue 8, 2007, Pages 473-476

  Tahara, Hiroki ^a   Kojima, Akira ^a   Hirokawa, Tomoyuki ^a   Oyama, Tatsuya ^a   Naganuma, Atsushi ^a   Maruta, Sakae ^a   Okada, Katsuyuki ^a   Ban, Satoshi ^a   Yoshida, Katsue ^a   Takagi, Hitoshi ^b   Mori, Masatomo ^b  

^a Kiryu Kosei General Hospital   (Japan)

^b GUNMA UNIVERSITY   (Japan)

Author keywords

Chronic hepatitis C; Consensus interferon; Interferon alphacon 1 therapy; Systemic sclerosis

Indexed keywords

ALPHA TOCOPHEROL NICOTINATE; ANTIHYPERTENSIVE AGENT; ANTINUCLEAR ANTIBODY; CONSENSUS INTERFERON;

ACROCYANOSIS; AGED; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CASE REPORT; CLINICAL FEATURE; FEMALE; HAND EDEMA; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOMODULATION; LABORATORY TEST; LIVER BIOPSY; LUNG TUBERCULOSIS; NAIL DISEASE; PHYSICAL EXAMINATION; PLEURISY; RAYNAUD PHENOMENON; SCLERODERMA; SCLEROSIS; SIDE EFFECT; SKIN ATROPHY; SKIN BIOPSY; SKIN DEFECT; SYSTEMIC SCLEROSIS; VIRUS LOAD;

AGED; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON TYPE I, RECOMBINANT; SCLERODERMA, SYSTEMIC;

EID: 34247381209     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.46.6328     Document Type: Article

References (26)

1. Yasuda S, Miyata K. Interferon alfacon-1(Advaferon): a novel synthetic interferon for the treatment of hepatitis C, its pharmacological and clinical profile. Nippon Yakurigaku Zasshi 120: 421-426, 2002 (in Japanese, Abstract in English).
2. Doi F, Kakizaki S, Takagi H, et al. Long-term outcome of interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C. Liver Int 25: 242-246, 2005.
3. Niewold TB, Swedler WI. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin Rheumatol 24: 178-181, 2005.
4. Okanoue T, Sakamoto S, Itoh Y, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 25: 283-291, 1996.
5. Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum 43: 1431-1442, 2000.
6. Mori S. Preliminary criteria in Japan. scleroderma International Symposium. Current Topics in Scleroderma, 1992: 17-26.
7. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23: 581-590, 1980.
8. Fritzsch J, Krug J, Heberling HJ. Interferon therapy and autoimmunity. Med Klin (Munich) 92: 265-272, 1997 (in German, Abstract in English).
9. Wilson LE, Widman D, Dikman SH, Gorevic PD. Autoimmune disease complicating antiviral therapy for hepatitis C virus infection. Semin Arthritis Rheum 32: 163-173, 2002.
10. Pellicano R, Smedile A, Peyre S, et al. Autoimmune manifestation during interferon therapy in patients with chronic hepatitis C:the hepatologist's view. Minerva Gastroenterol Dietol 51: 55-61, 2005.
11. Solans R, Bosch JA, Esteban I, Vilardell M. Systemic sclerosis developing in association with the use of interferon alpha therapy for chronic viral hepatitis. Clin Exp Rheumatol 22: 625-628, 2004.
12. Beretta L, Caronni M, Vanoli M, Scorza R, Systemic sclerosis. development after interferon-alpha therapy for myeloproliferative disorders. Br J Dermatol 147: 385-410, 2002.
13. Passiu G, Cauli A, Atzeni F, et al. Bleomycin-induced scleroderma: report of a case with a chronic course rather than the typical acute/ subacute self-limiting form. Clin Rheumatol 18: 422-424, 1999.
14. Hassett G, Harnett P, Manolios N. Scleroderma in association with the use of docetaxel (taxotere) for breast cancer. Clin Exp Rheumatol 19: 197-200, 2001.
15. Gilliland BC. Systemic sclerosis (scleroderma). In: Harrison:Principles of Internal Medicine. 13th ed (international edition). Isserbcher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL, Eds. McGraw-Hill, New York, 1994: 1665-1671.
16. Leroy EC. Connective tissue synthesis by scleroderma skin fibroblasts in cell culture. J Exp Med 135: 1351-1362, 1972.
17. Black CM, Silman AJ, Herrick AI, et al. Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma:results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 42: 299-305, 1999.
18. Kantor, TV, Friberg D, Medsger TA Jr, Buckingham RB, Whiteside TL. Cytokine production and serum levels in systemic sclerosis.. Clin Immunol Immunopathol 65: 278-285, 1992.
19. Gluszko P, Undas A, Kwasny B, Musial J, Szczeklik A. Treatment with interferon gamma enhances fibrinolysis in systemic sclerosis. Thromb Res 91: 203-207, 1998.
20. Varga J, Olsen A, Herhal J, Constantine G, Rosembloom J, Jimenez SA. IFN-γ reverses the stimulation of collagen but not fibronectin gene expression by TGF-β. Eur J Clin Invest 20: 487-492, 1990.
21. Roberts AB, Sporn MB, Assoian RK, et al. Transforming growth factor-β: rapid induction of fibrosis and angiogenesis in vitro and stimulation of collagen formation in vitro. Proc Natl Acad Sci U S A 83: 4167-4171, 1998.
22. Black CM, Silman AJ, Herrick AI, et al. Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 42: 299-305, 1999.
23. Grassegger A,Schuler G, Hessenberger G, et al. Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial. Br J Dermatol 139: 639-648, 1998.
24. Vlachoyiannopoulos PG, Tsifetaki N, Dimitriou I, Galaris D, Papiris SA, Moutsopoulos HM. Safety and efficacy of recombinant gamma interferon in the treatment of systemic sclerosis. Ann Rheum Dis 55: 761-768, 1996.
25. Rosembloom J, Feldman G, Freundlich B, Jimenez S. Inhibition of excessive scleroderma fibroblast collagen production by recombinant gamma-interferon. Association with a coordinate decrease in type I and III procollagen messenger RNA levels. Arthritis Rheum 29: 851-856, 1986.
26. Elefsiniotis IS, Vezali E, Kamposioras K, et al. Late onset autoimmune thrombocytopenia associated with pegylated interferon-alpha-2b plus ribavirin treatment for chronic hepatitis C. J Gastroenterol Hepatol 21: 622-623, 2006.